Newton, United States
Elevian, Inc., founded in 2018, is pioneering the development of new medicines aimed at promoting recovery and regeneration, with a key focus on post-stroke treatment. Headquartered in the United States, the company is spearheading its efforts with a lead program that employs a recombinant protein, targeting the crucial recovery phase following a stroke—an area that currently lacks viable therapeutic options.
The potential impact of Elevian's medicines extends beyond stroke recovery, offering the possibility to treat and prevent a variety of aging-associated diseases through regeneration promotion. This positions the company as a promising player in the biopharmaceutical sector.
Backed by a $40.00M Series A investment secured on 01 September 2021, Elevian has attracted support from notable investors such as Bold Capital Partners, Prime Movers Lab, Kuelbs Family Office, Caleb Bell, and Leslie Ventures. These investors underscore the confidence in the company's innovative approach and its potential to significantly impact healthcare markets.
